Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United Kingdom
  4. London Stock Exchange
  5. GlaxoSmithKline plc
  6. News
  7. Summary
    GSK   GB0009252882

GLAXOSMITHKLINE PLC

(GSK)
  Report
Real-time Estimate Quote. Real-time Estimate Cboe Europe - 08/03 03:55:06 am
1439.7 GBX   +0.85%
03:19aSanofi to buy U.S. mRNA partner Translate Bio in $3.2 billion deal
RE
02:01aRIGHTS AND ISSUES INVESTMENT TRUST PLC : Half Year -3-
DJ
01:53aSanofi makes $3.2 bln offer for U.S. mRNA partner Translate Bio
RE
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

CureVac may let contractors make rival vaccines if own shot fails - CEO

06/17/2021 | 12:14pm EDT

FRANKFURT, June 17 (Reuters) - German biotech firm CureVac could allow its network of manufacturing partners to be repurposed to make vaccines developed by other companies should its own experimental shot fail, its chief executive told Reuters on Thursday.

The German company saw billions of euros wiped from its market value on Thursday after its COVID-19 vaccine proved only 47% effective in an initial trial read-out, denting investor confidence in its ability to take on rival shots.

"At the moment we are of course fully committed to obtain authorisation, the data will show," CureVac CEO Franz-Werner Haas told Reuters TV, referring to a final read-out that is still pending.

"If this capacity is not to be used - we are working with a whole network of outstanding partners - ... these partners would of course be free to make other products if we don't have a product," he said.

CureVac's manufacturing partners include Celonic Group of Switzerland, Novartis, Bayer, Fareva, Wacker and Rentschler Biopharma SE.

However Haas stressed that CureVac's efforts to develop a new generation of vaccines, a venture where it collaborates with GlaxoSmithKline, would take precedence and that he would continue to draw on the external contractors for that drive

(Reporting by Tilman Blasshofer, Ludwig Burger and Patricia Weiss; Editing by Pravin Char)


ę Reuters 2021
Stocks mentioned in the article
ChangeLast1st jan.
BAYER AG 0.08% 50.55 Delayed Quote.4.89%
GLAXOSMITHKLINE PLC 0.84% 1439.8 Delayed Quote.6.38%
NOVARTIS AG 0.61% 84.27 Delayed Quote.0.14%
WACKER CHEMIE AG -0.12% 124.7 Delayed Quote.6.81%
All news about GLAXOSMITHKLINE PLC
03:19aSanofi to buy U.S. mRNA partner Translate Bio in $3.2 billion deal
RE
02:01aRIGHTS AND ISSUES INVESTMENT TRUST P : Half Year -3-
DJ
01:53aSanofi makes $3.2 bln offer for U.S. mRNA partner Translate Bio
RE
08/02GLAXOSMITHKLINE : Seeks US Approval for Measles, Mumps, Rubella Vaccine
MT
08/02Sanofi offers to buy U.S. biotech, mRNA partner Translate Bio -sources
RE
08/02GLAXOSMITHKLINE : Seeks Approval for Measles, Mumps, Rubella Vaccine in US
MT
08/02GLAXOSMITHKLINE : Gsk - Files For Licensure Of Mmr Vaccine In U.S.
RE
08/02PRESS RELEASE : Addex Appoints Seasoned Pharma Drug Researcher Mikhail Kaliniche..
DJ
08/02MARKET CHATTER : UK Government Investments Could Appoint GSK Director As Chair
MT
07/30GSK Receives Authorization Under Health Canada's Interim Order for Sotrovimab..
CI
More news
Financials
Sales 2021 33 304 M 46 269 M 46 269 M
Net income 2021 3 711 M 5 156 M 5 156 M
Net Debt 2021 21 137 M 29 366 M 29 366 M
P/E ratio 2021 19,3x
Yield 2021 5,60%
Capitalization 71 450 M 99 309 M 99 266 M
EV / Sales 2021 2,78x
EV / Sales 2022 2,61x
Nbr of Employees 94 066
Free-Float 92,2%
Chart GLAXOSMITHKLINE PLC
Duration : Period :
GlaxoSmithKline plc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GLAXOSMITHKLINE PLC
Short TermMid-TermLong Term
TrendsNeutralBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 27
Last Close Price 1 427,60 GBX
Average target price 1 534,54 GBX
Spread / Average Target 7,49%
EPS Revisions
Managers and Directors
Emma N. Walmsley Chief Executive Officer & Executive Director
Iain James Mackay Chief Financial Officer & Executive Director
Jonathan Richard Symonds Non-Executive Chairman
Karenann K. Terrell Chief Digital & Technology Officer
Hal V. Barron Executive Director & Chief Scientific Officer
Sector and Competitors
1st jan.Capi. (M$)
GLAXOSMITHKLINE PLC6.38%99 309
JOHNSON & JOHNSON9.46%453 313
ROCHE HOLDING AG13.38%337 105
PFIZER, INC.19.42%239 637
NOVARTIS AG0.28%225 343
ELI LILLY AND COMPANY46.06%221 348